-transparent.png){kind=logo}
At present, significant numbers of children with ALL enjoy prolonged survival without serious sequelae. All children should be given the benefit of treatment under the supervision of physicians experienced in childhood cancer. Risk factors should be properly assessed and children at high risk placed in innovative programs. Longterm follow-up of patients is essential to detect, as early as possible, potentially prohibitive toxicity.
Related Publications
W A Smithson, and
G S Gilchrist, and
E O Burgert
April 1976,
Comprehensive therapy,
W A Smithson, and
G S Gilchrist, and
E O Burgert
April 1982,
Journal of the Medical Association of Georgia,
W A Smithson, and
G S Gilchrist, and
E O Burgert
January 1974,
Seminars in hematology,
W A Smithson, and
G S Gilchrist, and
E O Burgert
January 1979,
Haematology and blood transfusion,
W A Smithson, and
G S Gilchrist, and
E O Burgert
December 1970,
The Journal of pediatrics,
W A Smithson, and
G S Gilchrist, and
E O Burgert
November 1978,
Cancer,
W A Smithson, and
G S Gilchrist, and
E O Burgert
November 1982,
Cancer research,
W A Smithson, and
G S Gilchrist, and
E O Burgert
July 1982,
[Rinsho ketsueki] The Japanese journal of clinical hematology,
W A Smithson, and
G S Gilchrist, and
E O Burgert
January 1981,
Cancer,
W A Smithson, and
G S Gilchrist, and
E O Burgert
May 1978,
Cancer treatment reports,
